Biocon Biologics partners with Adagio Therapeutics to advance antibody for COVID-19 prevention & treatment

ADG20 is a novel monoclonal antibody, targeting the spike protein of related Coronaviruses and SARS-CoV-2. It is currently in global clinical development by Adagio as a single agent for both prevention and treatment of Coronavirus.

The fully-integrated biosimilars company, Biocon Biologics Ltd, a subsidiary of Biocon Ltd reported that US-based Adagio Therapeutics has granted them an exclusive licence to manufacture and commercialise, broadly neutralising antibody treatment based on ADG20 for India as well as select emerging markets. 

ADG20 is a novel monoclonal antibody, targeting the spike protein of related Coronaviruses and SARS-CoV-2. It is currently in global clinical development by Adagio as a single agent for both prevention and treatment of Coronavirus. 

According to the initial data, ADG20 could furnish durable and rapid protection against COVID-19 for up to one year. This could help to significantly reduce COVID-19-related hospitalisations and prevent infections. ADG20 has the potential to address several resistant variants such as the Delta variant. It will be administered as a single intramuscular injection. 

Adagio Therapeutics has already published preliminary data from its ongoing phase 1 trial. They are currently conducting two global phase 2/3 clinical trials. 

Adagio plans to seek emergency use authorisation (EUA) in the US as early as the first quarter of 2022. Under the terms of the deal, Biocon Biologics will get access to the clinical and nonclinical data from Adagio’s EUA submission to United States Food & Drug Administration (USFDA) to seek approvals in the emerging markets. 

Biocon Biologics has a comprehensive COVID-19 portfolio that addresses the needs of patients at different stages of the virus such as critical, severe, moderate, and mild. In India, more than 50,000 patients have benefited from its COVID-19 drugs that included Itolizumab, CytoSorb & Remdesivir.